AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Psychedelicalpha

Published November 12, 2026

220 Patients or 20000? Clinics Split on Psychedelics ' First Year

Read the full story at Psychedelicalpha

The panel was moderated by Joy Sun Cooper, Senior Advisor at the Psychedelic Science Funders Collaborative, and featured: Myriam Barthes, CEO & Co-.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics